Navigation Links
Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon
Date:10/24/2009

LOUISVILLE, Ky., Oct. 23 /PRNewswire/ -- Potentia Pharmaceuticals, a privately-held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), announced today that it has entered into licensing and purchase option agreements with Alcon Research, Ltd., a wholly-owned subsidiary of Alcon, Inc. (NYSE: ACL). The agreements provide Alcon with a license to develop Potentia's leading drug candidate, POT-4, for the treatment of AMD. The agreements also provide for Alcon to acquire the shares of Potentia if specified development milestones are achieved and if Alcon elects to continue development of POT-4.

Alcon will make upfront payments to Potentia for the initial license and option rights. The agreements also provide for potential future payments to Potentia's shareholders based on the achievement of multiple clinical and global regulatory approval milestones for several therapeutic indications and on Alcon's decision to proceed with development. They also provide for sales-based royalty payments to Potentia's shareholders on any products that are ultimately approved and commercialized. Financial terms were not disclosed.

"Alcon is the proven leader in the clinical development and marketing of eye care products and compounds. We could not wish for a better company to develop POT-4 into a new treatment option for the millions of patients with macular degeneration," said Cedric Francois, President and CEO of Potentia Pharmaceuticals.

POT-4 was the first complement inhibitor to enter the clinic for ophthalmological use and is being developed as a potential treatment for both dry and wet AMD. Potentia has completed a Phase I trial for POT-4 in patients with wet AMD. The trial was designed to determine the safety and tolerability of an intravitreal injection of POT-4, as well as its stability and depot-forming properties. In the study investigators observed only minimal and
'/>"/>

SOURCE Potentia Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Bionovo Announces Publication of Data on Potential Increase in Breast Cancer Risk Due to the Inhibitory Effect of Tamoxifen Treatment on Estrogen Receptor Beta
2. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
3. Texas State Tests Potential New Cancer-Fighting Weapon
4. Metabolic Solutions Development Company To Test Potential Treatment for Alzheimers
5. Hamon Tower Features Critical Care Advances, Potential for Reduced Costs
6. OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer
7. EMD Serono Submits Application for Cladribine Tablets as a Potential Oral Short-Course Multiple Sclerosis Therapy in the United States
8. Pivotal Registration Trial of OPAXIO Maintenance Therapy in First-Line Ovarian Cancer Reaches Enrollment Milestone of 600 patients, Cell Therapeutics and the Gynecologic Oncology Group Discuss Potential for Early Interim Analysis
9. Researchers Identify Two Genes as Potential Therapeutic Targets for Multiple Sclerosis
10. Potential Skin Cancer Breakthrough Tested at Scottsdale Healthcare Published Today in New England Journal of Medicine
11. Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrines Cotara(R) for Treatment of Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014 Apnea Sciences ( www.apneasciences.com ... in Aliso Viejo , California.  ... the tremendous growth and worldwide expansion, a new facility ... SnoreRx, the anti snore cure have exceeded our expectations ... "We are now in 23 countries and will be ...
(Date:12/22/2014)... 2014 Research and Markets ( ... "Investment Analysis of the US Medical Device ... http://photos.prnewswire.com/prnh/20130307/600769 ... device sector identifies the key trends and rationale ... and mergers and acquisitions. The study ...
(Date:12/22/2014)... Pa. and STOCKHOLM , ... (publ) (Sobi) and partner Auxilium Pharmaceuticals, Inc. today announced ... (CHMP) of the European Medicines Agency (EMA) has adopted ... clostridium histolyticum) for the treatment of adult men with ... of at least 30 degrees at the start of ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6
... Texas, Sept. 29 Luminex Corporation (Nasdaq: ... 2010 Prix Galien USA Award for its innovative xTAG® ... named Best Medical Technology at the Prix Galien USA ... 2010, at the American Museum of Natural History in ...
... asked today to make protecting the eyes from ... by increasing the prevalence of UV and eye-health ... as the Surgeon General, and in upcoming healthcare ... the Congressional Vision Caucus, provided the opening remarks ...
Cached Medicine Technology:Luminex Corporation Wins Prestigious 2010 Prix Galien USA Award 2Prevent Blindness America Issues Call-to-Action to Make UV Eye Protection a National Health Priority 2Prevent Blindness America Issues Call-to-Action to Make UV Eye Protection a National Health Priority 3
(Date:12/24/2014)... New York, New York (PRWEB) December 24, 2014 ... lawsuits ( http://www.xareltolawsuit2015.com/ ) that allege the blood ... other complications has outlined a leadership structure for ... an Order dated December 17th, the Court plans ... for the parties and also plans on appointing ...
(Date:12/24/2014)... 2014 BambooIndustry.com a famous bamboo flooring ... Today, the company announces its multiple layer bamboo ... on these new products. , Bamboo panel is the ... multiple layer bamboo panel board features high quality selective ... emissions free. The bamboo panel consists of multiple layers ...
(Date:12/24/2014)... 2014 (HealthDay News) -- Adults who experienced childhood ... migraine headaches, suggests a study published online Dec. ... "Childhood maltreatment can have long-lasting effects, like associated ... study author Dawn Buse, director of behavioral medicine ... said in a journal news release. "When ...
(Date:12/24/2014)... CA (PRWEB) December 24, 2014 Gluten, ... havoc on those who have an intolerance to gluten, ... diarrhea, gas, bloating, migraine headaches, joint pain and fatigue. ... free diet plans that deliver safe and fast ... foods that trigger a gluten allergy reaction. These gluten ...
(Date:12/24/2014)... The report offers details on the global sports ... such as the key trends, the orthopedic market, the ... U.S. sports medicine, the impact of the global economy ... by the market. , Browse report with table of ... provides an overview of the global as well as ...
Breaking Medicine News(10 mins):Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3Health News:Bamboo Flooring Company Bambooindustry.com Introduces Its Multiple Layer Bamboo Panel Board Collection 2Health News:Abuse in Childhood Tied to Migraines in Adulthood 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 3Health News:Sports Medicine Market Report 2014: Global Industry Analysis, Share, Size, Trends, Growth and Forecast report 2
... July 18 (HealthDay News) -- Correcting lazy eye in adults ... been able to do that -- at least partially and ... Someone with lazy eye -- ophthalmologists call it amblyopia -- ... other. Early treatment often has a child wearing a patch ...
... July 18 Two consumer,groups today filed an ... human embryonic stem cells held by the Wisconsin ... Foundation for Taxpayer and Consumer,Rights, and the Public ... of Appeals and Interferences. The PTO examiner narrowed,WARF,s ...
... in French . , Winnipeg (July ... Canadian Institutes of Health Research (CIHR) was announced today ... Secretary for Health, on behalf of Tony Clement, Minister ... investigating how to improve the application of mental health ...
... New research led by a Michigan State University scholar ... more emotionally unstable and harder to get along with ... employers are urged to guard against the use of ... firing. , Mark Roehling, associate professor of human resource ...
... national immunization awareness campaign to raise awareness, of ... ... CHEVY CHASE, Md., July 18 The COSHAR Foundation, a,nonprofit ... on minority and disadvantaged populations, hosts,National Women,s Health Awareness Day ...
... Blue Shield,United Concordia Companies, Inc. and Catholic Charities ... for Pittsburghers. Beginning at 10,a.m. and continuing until ... will,offer health information and dental screenings, restorations and ... long, oral health has received much less attention ...
Cached Medicine News:Health News:Magnetic Pulses to Brain Improve Lazy Eye in Adults 2Health News:Magnetic Pulses to Brain Improve Lazy Eye in Adults 3Health News:Consumer Groups File Appeal on Challenge of Human Stem Cell Patent Held By WARF 2Health News:CIHR announces $4.4 million to improve mental health of Canadians 2Health News:Studies refute common stereotypes about obese workers 2Health News:The COSHAR Foundation Participates in Annual Women's Health Awareness Day 2Health News:The COSHAR Foundation Participates in Annual Women's Health Awareness Day 3Health News:Highmark Blue Cross Blue Shield, United Concordia and Catholic Charities Join Forces to Offer Free Health, Dental Services This Saturday 2
... Compressor provides effective therapy at an affordable price. ... home or on the go and features ease ... reliable operation you have come to count on ... the perfect solution for those patients seeking a ...
... delivery is an important part of managing ... and convenient products mean delivering the aerosolized ... time while minimizing medication waste. Aerosol delivery ... line of Nebulizers, including the new NebuTech® ...
... SynergyPlus+ is recommended for people with low ... limbs associated with failed back syndrome, low ... people with post laminectomy pain, multiple back ... disease and Complex Regional Pain Syndrome (CRPS). ...
Whether you require high flow rates for critical situations or lower rates for others, this insufflator handles both situations equally well, regulated by the preselected pressure....
Medicine Products: